A new personalized mRNA vaccine, when used in conjunction with Keytruda, may significantly reduce the recurrence of melanoma after surgical removal, according to a recent large clinical trial.
This potential breakthrough offers hope for patients facing the risk of melanoma returning after initial treatment. The trial suggests the vaccine helps the body’s immune system recognize and fight any remaining cancer cells, preventing the disease from resurfacing.
The vaccine is personalized, meaning it is designed specifically for each patient’s cancer. This approach, combined with Keytruda – an immunotherapy drug – aims to bolster the immune response against melanoma. The source does not detail how the personalization is achieved or the mechanism by which the mRNA vaccine functions, only that it is paired with Keytruda to achieve a potentially improved outcome for skin cancer patients following surgery.
Read the original coverage
💬 Comments
📜 Comment Policy